Fluid resuscitation

PreclinicalSmall molecule

UUniversity of Zurich

Fluid resuscitation is one of 52 small molecule programs targeting Shock. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ShockUnknown status

Septic ShockActive, not recruiting

ShockPreclinical

Unknown status

Septic ShockPreclinical

Active, not recruiting

Competition

Competitive Landscape

72 competitors in Septic Shock

#DrugCompanyPhaseTrials

Proamatine

Takeda

Approved

4 2

Primacor

Sanofi

Approved

2 3

Versed

CConrado Roberto Hoffmann Filho

Approved

4 4

Ketalar

AAultman Health Foundation

Approved

3 5

Duragesic

CCephalon

Approved

2 6

Florinef

Jazz Pharmaceuticals

Phase 3

5 7

Cyklokapron

JJ Molner

Approved

—8

Methylthioninium Chloride

PProvepharm SAS

Phase 3

10 9

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

9 10

Albumin

LLaboratoire français de Fractionnement et de Biotechnologies

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Injury2 trials

Early Fluid Resuscitation With Balanced HES 130/0.4 [6%] in Severe Burn Injury

Unknown status·UUniversity of Zurich·Phase 4·NCT01012648·48 enrolled

Fluid Resuscitation With HES 200/0.5 10% in Severe Burn Injury

Completed·UUniversity of Zurich·Phase 3·NCT01120730·28 enrolled

Septic Shock1 trial

Acetated Ringer's Solution Versus Saline in Patients With Septic Shock

Unknown status·SSoutheast University, China·N/A·NCT04507672·2,000 enrolled

Shock1 trial

Crystalloids for AKI in Shock Patients

Unknown status·SSoutheast University, China·N/A·NCT03188614·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Fluid resuscitation. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Fluid resuscitation compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Fluid resuscitation. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Zurich company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Zurich

Fluid resuscitation

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Injury2 trials

Septic Shock1 trial

Shock1 trial

References

Drug Info

Quick Facts

Related News